Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
ALIOF's Cash to Debt is ranked higher than
88% of the 940 Companies
in the Global Biotechnology industry.

( Industry Median: 101.30 vs. ALIOF: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ALIOF' s Cash to Debt Range Over the Past 10 Years
Min: 2.7  Med: 4.08 Max: No Debt
Current: No Debt
Equity to Asset 0.71
ALIOF's Equity to Asset is ranked higher than
51% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.70 vs. ALIOF: 0.71 )
Ranked among companies with meaningful Equity to Asset only.
ALIOF' s Equity to Asset Range Over the Past 10 Years
Min: 0.5  Med: 0.61 Max: 0.72
Current: 0.71
0.5
0.72
Interest Coverage 123.88
ALIOF's Interest Coverage is ranked lower than
61% of the 375 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ALIOF: 123.88 )
Ranked among companies with meaningful Interest Coverage only.
ALIOF' s Interest Coverage Range Over the Past 10 Years
Min: 0.55  Med: 50.79 Max: 9999.99
Current: 123.88
0.55
9999.99
F-Score: 6
Z-Score: 21.20
M-Score: -2.69
WACC vs ROIC
8.90%
61.97%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 31.81
ALIOF's Operating margin (%) is ranked higher than
92% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -72.99 vs. ALIOF: 31.81 )
Ranked among companies with meaningful Operating margin (%) only.
ALIOF' s Operating margin (%) Range Over the Past 10 Years
Min: 0.68  Med: 24.79 Max: 32.06
Current: 31.81
0.68
32.06
Net-margin (%) 26.94
ALIOF's Net-margin (%) is ranked higher than
91% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -74.36 vs. ALIOF: 26.94 )
Ranked among companies with meaningful Net-margin (%) only.
ALIOF' s Net-margin (%) Range Over the Past 10 Years
Min: -8.15  Med: 21.04 Max: 30.33
Current: 26.94
-8.15
30.33
ROE (%) 38.74
ALIOF's ROE (%) is ranked higher than
97% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -31.54 vs. ALIOF: 38.74 )
Ranked among companies with meaningful ROE (%) only.
ALIOF' s ROE (%) Range Over the Past 10 Years
Min: -8.85  Med: 27.86 Max: 53.58
Current: 38.74
-8.85
53.58
ROA (%) 26.09
ALIOF's ROA (%) is ranked higher than
97% of the 944 Companies
in the Global Biotechnology industry.

( Industry Median: -26.66 vs. ALIOF: 26.09 )
Ranked among companies with meaningful ROA (%) only.
ALIOF' s ROA (%) Range Over the Past 10 Years
Min: -5.18  Med: 14.90 Max: 23.67
Current: 26.09
-5.18
23.67
ROC (Joel Greenblatt) (%) 135.45
ALIOF's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -357.95 vs. ALIOF: 135.45 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ALIOF' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -8.98  Med: 103.40 Max: 168.62
Current: 135.45
-8.98
168.62
Revenue Growth (3Y)(%) 7.50
ALIOF's Revenue Growth (3Y)(%) is ranked higher than
57% of the 491 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. ALIOF: 7.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ALIOF' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -25.9  Med: 3.70 Max: 21.5
Current: 7.5
-25.9
21.5
EBITDA Growth (3Y)(%) 16.50
ALIOF's EBITDA Growth (3Y)(%) is ranked higher than
72% of the 493 Companies
in the Global Biotechnology industry.

( Industry Median: -0.70 vs. ALIOF: 16.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ALIOF' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -48.4  Med: 6.30 Max: 131.2
Current: 16.5
-48.4
131.2
EPS Growth (3Y)(%) 24.10
ALIOF's EPS Growth (3Y)(%) is ranked higher than
79% of the 499 Companies
in the Global Biotechnology industry.

( Industry Median: -5.10 vs. ALIOF: 24.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ALIOF' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -35.8  Med: 6.80 Max: 47.6
Current: 24.1
-35.8
47.6
» ALIOF's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-21)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with ALIOF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:XSWX:RO, OCSE:NOVO B, NAS:AMGN, NAS:GILD, NAS:CELG, NAS:BIIB » details
Traded in other countries:ACT.Germany, ATLNE.Switzerland, 0QMN.UK,
Actelion Ltd is a biopharmaceutical company engaged in the discovery, development and commercialization of drugs for diseases with unmet medical needs.

Actelion Ltd was founded on December 17, 1997 and is headquartered in Allschwil, Switzerland. The Company is a biopharmaceutical company, that engages in the discovery, development, and commercialization of low molecular weight drugs for unmet medical needs. It is engaged in the field of pulmonary arterial hypertension (PAH). Its portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications. Its products portfolio includes Opsumit (Macitentan), Tracleer (Bosentan), Valchlor (Mechlorethamine), Zavesca (Miglustat), Veletri (Epoprostenol For Injection), and Ventavis (Iloprost).

Ratios

vs
industry
vs
history
P/E(ttm) 30.88
ALIOF's P/E(ttm) is ranked lower than
52% of the 254 Companies
in the Global Biotechnology industry.

( Industry Median: 29.15 vs. ALIOF: 30.88 )
Ranked among companies with meaningful P/E(ttm) only.
ALIOF' s P/E(ttm) Range Over the Past 10 Years
Min: 11.02  Med: 18.75 Max: 36.63
Current: 30.88
11.02
36.63
Forward P/E 21.46
ALIOF's Forward P/E is ranked lower than
60% of the 94 Companies
in the Global Biotechnology industry.

( Industry Median: 17.15 vs. ALIOF: 21.46 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 30.88
ALIOF's PE(NRI) is ranked higher than
50% of the 244 Companies
in the Global Biotechnology industry.

( Industry Median: 30.43 vs. ALIOF: 30.88 )
Ranked among companies with meaningful PE(NRI) only.
ALIOF' s PE(NRI) Range Over the Past 10 Years
Min: 11.02  Med: 18.74 Max: 36.62
Current: 30.88
11.02
36.62
Price/Owner Earnings (ttm) 24.21
ALIOF's Price/Owner Earnings (ttm) is ranked higher than
60% of the 146 Companies
in the Global Biotechnology industry.

( Industry Median: 37.01 vs. ALIOF: 24.21 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
ALIOF' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 11.49  Med: 22.82 Max: 413.31
Current: 24.21
11.49
413.31
P/B 11.68
ALIOF's P/B is ranked lower than
88% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: 3.36 vs. ALIOF: 11.68 )
Ranked among companies with meaningful P/B only.
ALIOF' s P/B Range Over the Past 10 Years
Min: 2.35  Med: 4.06 Max: 12.19
Current: 11.68
2.35
12.19
P/S 8.37
ALIOF's P/S is ranked higher than
61% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 12.41 vs. ALIOF: 8.37 )
Ranked among companies with meaningful P/S only.
ALIOF' s P/S Range Over the Past 10 Years
Min: 1.96  Med: 3.95 Max: 8.82
Current: 8.37
1.96
8.82
PFCF 25.64
ALIOF's PFCF is ranked higher than
55% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 26.95 vs. ALIOF: 25.64 )
Ranked among companies with meaningful PFCF only.
ALIOF' s PFCF Range Over the Past 10 Years
Min: 8.66  Med: 23.35 Max: 183.52
Current: 25.64
8.66
183.52
POCF 24.13
ALIOF's POCF is ranked higher than
51% of the 203 Companies
in the Global Biotechnology industry.

( Industry Median: 24.65 vs. ALIOF: 24.13 )
Ranked among companies with meaningful POCF only.
ALIOF' s POCF Range Over the Past 10 Years
Min: 8.45  Med: 16.87 Max: 135.26
Current: 24.13
8.45
135.26
EV-to-EBIT 24.39
ALIOF's EV-to-EBIT is ranked higher than
50% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 24.27 vs. ALIOF: 24.39 )
Ranked among companies with meaningful EV-to-EBIT only.
ALIOF' s EV-to-EBIT Range Over the Past 10 Years
Min: -110.1  Med: 15.35 Max: 30.8
Current: 24.39
-110.1
30.8
EV-to-EBITDA 21.55
ALIOF's EV-to-EBITDA is ranked lower than
51% of the 304 Companies
in the Global Biotechnology industry.

( Industry Median: 21.30 vs. ALIOF: 21.55 )
Ranked among companies with meaningful EV-to-EBITDA only.
ALIOF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -77.3  Med: 15.70 Max: 206.8
Current: 21.55
-77.3
206.8
PEG 0.96
ALIOF's PEG is ranked higher than
81% of the 93 Companies
in the Global Biotechnology industry.

( Industry Median: 2.28 vs. ALIOF: 0.96 )
Ranked among companies with meaningful PEG only.
ALIOF' s PEG Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: 0.96
Current Ratio 2.56
ALIOF's Current Ratio is ranked lower than
69% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.55 vs. ALIOF: 2.56 )
Ranked among companies with meaningful Current Ratio only.
ALIOF' s Current Ratio Range Over the Past 10 Years
Min: 1.75  Med: 2.33 Max: 3.95
Current: 2.56
1.75
3.95
Quick Ratio 2.32
ALIOF's Quick Ratio is ranked lower than
68% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.27 vs. ALIOF: 2.32 )
Ranked among companies with meaningful Quick Ratio only.
ALIOF' s Quick Ratio Range Over the Past 10 Years
Min: 1.7  Med: 2.26 Max: 3.8
Current: 2.32
1.7
3.8
Days Inventory 132.56
ALIOF's Days Inventory is ranked lower than
52% of the 446 Companies
in the Global Biotechnology industry.

( Industry Median: 127.50 vs. ALIOF: 132.56 )
Ranked among companies with meaningful Days Inventory only.
ALIOF' s Days Inventory Range Over the Past 10 Years
Min: 88.91  Med: 102.47 Max: 127.68
Current: 132.56
88.91
127.68

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.97
ALIOF's Dividend Yield is ranked lower than
60% of the 206 Companies
in the Global Biotechnology industry.

( Industry Median: 1.23 vs. ALIOF: 0.97 )
Ranked among companies with meaningful Dividend Yield only.
ALIOF' s Dividend Yield Range Over the Past 10 Years
Min: 0.82  Med: 1.35 Max: 2.7
Current: 0.97
0.82
2.7
Dividend Payout 0.25
ALIOF's Dividend Payout is ranked higher than
61% of the 115 Companies
in the Global Biotechnology industry.

( Industry Median: 0.31 vs. ALIOF: 0.25 )
Ranked among companies with meaningful Dividend Payout only.
ALIOF' s Dividend Payout Range Over the Past 10 Years
Min: 0.47  Med: 0.94 Max: 1.16
Current: 0.25
0.47
1.16
Dividend Growth (3y) 17.60
ALIOF's Dividend Growth (3y) is ranked higher than
77% of the 90 Companies
in the Global Biotechnology industry.

( Industry Median: 6.30 vs. ALIOF: 17.60 )
Ranked among companies with meaningful Dividend Growth (3y) only.
ALIOF' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 17.6
Current: 17.6
0
17.6
Forward Dividend Yield 0.97
ALIOF's Forward Dividend Yield is ranked lower than
62% of the 193 Companies
in the Global Biotechnology industry.

( Industry Median: 1.34 vs. ALIOF: 0.97 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 0.97
ALIOF's Yield on cost (5-Year) is ranked lower than
66% of the 241 Companies
in the Global Biotechnology industry.

( Industry Median: 1.53 vs. ALIOF: 0.97 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
ALIOF' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.82  Med: 1.35 Max: 2.7
Current: 0.97
0.82
2.7
3-Year Average Share Buyback Ratio 2.40
ALIOF's 3-Year Average Share Buyback Ratio is ranked higher than
97% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. ALIOF: 2.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ALIOF' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -81.7  Med: 1.40 Max: 2.4
Current: 2.4
-81.7
2.4

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 33.62
ALIOF's Price/Net Current Asset Value is ranked lower than
92% of the 783 Companies
in the Global Biotechnology industry.

( Industry Median: 4.96 vs. ALIOF: 33.62 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ALIOF' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 4.58  Med: 11.97 Max: 40.47
Current: 33.62
4.58
40.47
Price/Tangible Book 18.71
ALIOF's Price/Tangible Book is ranked lower than
90% of the 949 Companies
in the Global Biotechnology industry.

( Industry Median: 3.90 vs. ALIOF: 18.71 )
Ranked among companies with meaningful Price/Tangible Book only.
ALIOF' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.98  Med: 5.00 Max: 19.39
Current: 18.71
2.98
19.39
Price/Projected FCF 3.26
ALIOF's Price/Projected FCF is ranked higher than
54% of the 180 Companies
in the Global Biotechnology industry.

( Industry Median: 3.90 vs. ALIOF: 3.26 )
Ranked among companies with meaningful Price/Projected FCF only.
ALIOF' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.84  Med: 2.87 Max: 3.45
Current: 3.26
1.84
3.45
Price/Median PS Value 2.12
ALIOF's Price/Median PS Value is ranked lower than
83% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. ALIOF: 2.12 )
Ranked among companies with meaningful Price/Median PS Value only.
ALIOF' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.51  Med: 1.08 Max: 3.89
Current: 2.12
0.51
3.89
Price/Graham Number 5.06
ALIOF's Price/Graham Number is ranked lower than
71% of the 210 Companies
in the Global Biotechnology industry.

( Industry Median: 3.11 vs. ALIOF: 5.06 )
Ranked among companies with meaningful Price/Graham Number only.
ALIOF' s Price/Graham Number Range Over the Past 10 Years
Min: 1.41  Med: 2.50 Max: 5.44
Current: 5.06
1.41
5.44
Earnings Yield (Greenblatt) (%) 4.08
ALIOF's Earnings Yield (Greenblatt) (%) is ranked higher than
87% of the 1090 Companies
in the Global Biotechnology industry.

( Industry Median: -9.50 vs. ALIOF: 4.08 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ALIOF' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.2  Med: 5.65 Max: 12.1
Current: 4.08
3.2
12.1

More Statistics

Revenue (TTM) (Mil) $2,184
EPS (TTM) $ 5.32
Beta1.33
Short Percentage of Float0.00%
52-Week Range $122.00 - 162.39
Shares Outstanding (Mil)104.61

Analyst Estimate

Dec16 Dec17
Revenue (Mil $) 1,852 1,862
EPS ($) 5.54 5.97
EPS without NRI ($) 5.54 5.97
EPS Growth Rate
(3Y to 5Y Estimate)
14.09%
» More Articles for ALIOF

Headlines

Articles On GuruFocus.com
Actelion Still On Growth Track Feb 18 2015 

More From Other Websites
Actelion's Annual General Meeting of Shareholders held in Basel, Switzerland - All Board proposals... May 04 2016
United (UTHR) Stock Declines Despite Q1 Earnings Beat Apr 29 2016
ETF’s with exposure to Actelion Ltd. : April 22, 2016 Apr 22 2016
Actelion Ltd. :ALIOF-US: Earnings Analysis: Q1, 2016 By the Numbers Apr 22 2016
Very strong performance continues in the first quarter of 2016 - driven by outcome-based PAH... Apr 21 2016
Invitation: Actelion to discuss first quarter 2016 financial results Apr 14 2016
Clovis Hits 52-week Low Post Rociletinib Briefing Documents Apr 11 2016
Ionis Tanks, FDA Clinical Hold on IONIS-TTRRx Phase III Study Apr 08 2016
Intercept's (ICPT) Ocaliva Gets Favorable FDA Panel Vote Apr 08 2016
Illumina Unveils BaseSpace Suite, Boosts Precision Medicine Apr 08 2016
Seres Therapeutics (MCRB) in Focus: Stock Up 5.5% in Session Apr 08 2016
Ironwood Slumps, Halts Development of Gastroparesis Drug Apr 06 2016
Actelion issues invitation to 2016 Annual General Meeting of Shareholders Apr 06 2016
AbbVie Up, Wins CHMP Backing for Humira's Expanded Use Apr 05 2016
Abeona Therapeutics (ABEO) Jumps: Stock Rises 6.4% Apr 05 2016
Bristol-Myers Gets CHMP Backing for Opdivo's Expanded Use Apr 04 2016
Regeneron, Sanofi Up, Eczema Drug Tops Phase III Studies Apr 04 2016
The Zacks Analyst Blog Highlights: Actelion, Mesoblast, Kindred Biosciences and CorMedix Apr 04 2016
VIVUS (VVUS) in Focus: Stock Jumps 6.4% in Session Apr 04 2016
Positive CHMP opinion for Uptravi (selexipag) for the long-term treatment of pulmonary arterial... Apr 01 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)